UroGen Pharma Ltd.

XNASHealth care

Last traded price · USD

$28.72

−16.51%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:28 IST · A quote does not mean the product is available to trade on your account.

Day's open: $33.04
Previous close: $34.40
Volume: 2.9M
Day's high: $34.17
Day's low: $27.55

In brief

UroGen Pharma Ltd. is a health care company listed on Nasdaq, valued at about $1.40B.
Its shares closed at $28.74 on 4 Nov 2026, up 45.1% over the past year.
From India you can buy URGN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy UroGen Pharma Ltd. (URGN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole URGN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade URGN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −30.6% (SPY −1.6%, XLV +13.5%). 3 months: −38.1% (SPY −0.4%, XLV +15.5%). 1 year: +45.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: URGN, SPY and XLV · as of 4 Nov 2026
Fell 16.5% on 4 Nov 2026
The 4 Nov 2026 decline of 16.5% was 5.8× its average daily move of 2.8% over the past year, and its largest one-day decline since 21 May 2025.
Daily closes, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $28.74 was 27.4% below its 50-day average ($39.60) and 8.8% below its 200-day average ($31.51). It has closed below the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 6 May 2026, 126 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 11.5% of shares outstanding
5.6M shares were sold short at the 15 Oct 2026 settlement, 11.5% of the 48.9M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.7× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.9M shares was 2.7× the average of the 30 sessions before it (1.1M), as the price fell 16.5%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−30.6%

6 months+9.5%

1 year+45.1%

5 years+50.9%

Newswire

About

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Website

Notable moves

June 12, 2025
+51.78%
May 21, 2025
−44.69%
July 27, 2023
+98.56%

Newswire

About

Website

Notable moves

June 12, 2025
+51.78%
May 21, 2025
−44.69%
July 27, 2023
+98.56%

UroGen Pharma Ltd.

XNASHealth care

Last traded price · USD

$28.72

−16.51%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:28 IST · A quote does not mean the product is available to trade on your account.

Day's open: $33.04
Previous close: $34.40
Volume: 2.9M
Day's high: $34.17
Day's low: $27.55

In brief

UroGen Pharma Ltd. is a health care company listed on Nasdaq, valued at about $1.40B.
Its shares closed at $28.74 on 4 Nov 2026, up 45.1% over the past year.
From India you can buy URGN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy UroGen Pharma Ltd. (URGN) shares from India?

Do I need the price of a whole URGN share to invest?

How much can I invest in US stocks in a year?

Can I trade URGN options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −30.6% (SPY −1.6%, XLV +13.5%). 3 months: −38.1% (SPY −0.4%, XLV +15.5%). 1 year: +45.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: URGN, SPY and XLV · as of 4 Nov 2026
Fell 16.5% on 4 Nov 2026
The 4 Nov 2026 decline of 16.5% was 5.8× its average daily move of 2.8% over the past year, and its largest one-day decline since 21 May 2025.
Daily closes, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $28.74 was 27.4% below its 50-day average ($39.60) and 8.8% below its 200-day average ($31.51). It has closed below the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 6 May 2026, 126 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 11.5% of shares outstanding
5.6M shares were sold short at the 15 Oct 2026 settlement, 11.5% of the 48.9M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.7× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.9M shares was 2.7× the average of the 30 sessions before it (1.1M), as the price fell 16.5%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−30.6%

6 months+9.5%

1 year+45.1%

5 years+50.9%

Newswire

About

Website

Notable moves

June 12, 2025
+51.78%
May 21, 2025
−44.69%
July 27, 2023
+98.56%

Newswire

About

Website

Notable moves

June 12, 2025
+51.78%
May 21, 2025
−44.69%
July 27, 2023
+98.56%

UroGen Pharma Ltd.

UroGen Pharma Ltd. in brief

Ahead of SPY and its sector fund XLV over 1 year

Fell 16.5% on 4 Nov 2026

Below its 50- and 200-day averages

Short interest at 11.5% of shares outstanding

Volume 2.7× its 30-session average on 4 Nov 2026

UroGen Pharma Ltd.

UroGen Pharma Ltd. in brief

Ahead of SPY and its sector fund XLV over 1 year

Fell 16.5% on 4 Nov 2026

Below its 50- and 200-day averages

Short interest at 11.5% of shares outstanding

Volume 2.7× its 30-session average on 4 Nov 2026